Developer docs
API playgroundTry for free, no card

Search company profiles

2seventy bio

Full company profile

uuid0000gk7

Namestring
2seventy bio
Legal namestring
2seventy bio, Inc.
Websiteurl
2seventybio.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

2seventy bio was an immuno-oncology cell therapy company founded in 2021 as a spinout of Bluebird bio, headquartered in Cambridge, Massachusetts. The company discovered, developed, and commercialized autologous CAR-T cell therapies, with its lead and sole commercial product being ABECMA (idecabtagene vicleucel), a BCMA-directed CAR-T therapy for adults with relapsed or refractory multiple myeloma. ABECMA is manufactured using a proprietary process that engineers each patient's own T cells to target BCMA-expressing cells, with a one-time treatment model positioned as a potentially durable option for patients who have exhausted prior lines of therapy. ABECMA generated $406 million in sales in 2024 per the input data, marketed in partnership with Bristol Myers Squibb.

2seventy bio operated a partner-led commercial model: BMS provided the specialty distribution infrastructure, certified treatment center network, and field sales organization that marketed ABECMA to hematologists and oncology centers globally, while 2seventy bio contributed the cell therapy platform, manufacturing expertise, and clinical development. Revenue was generated through a combination of ABECMA product economics shared with BMS and contractual milestones, with cell therapies in this category typically priced at $400,000-$500,000 per patient. The company supplemented ABECMA with early-stage pipeline assets, notably bbT369, a CAR-T candidate for lymphoma that was sold to Regeneron in January 2024 for $5 million.

The company was financed primarily through a $170 million private placement in March 2022 led by a syndicate of healthcare-specialist investors including Bain Capital Life Sciences, EcoR1 Capital, Janus Henderson, and RTW Investments. Over its standalone life, 2seventy bio narrowed its scope to a single commercial asset and was acquired by Bristol Myers Squibb in March 2025 for approximately $286 million, with BMS taking full control of ABECMA and the underlying cell therapy platform.

Short descriptiontext

2seventy bio was an immuno-oncology cell therapy company, spun out of Bluebird bio in 2021, that developed and commercialized ABECMA, a BCMA-directed CAR-T therapy for relapsed/refractory multiple myeloma, in partnership with Bristol Myers Squibb before being acquired by BMS in March 2025.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
CAR-T cell therapy, immuno-oncology treatments, autologous cell therapy, multiple myeloma therapies, biopharmaceutical development
Industry1 code
PRIMARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Cell Therapy Oncology Biopharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Product Sales - ABECMA
TypeOne Time License
Description

Revenue from commercialization of ABECMA (idecabtagene vicleucel), a CAR-T cell therapy for multiple myeloma, marketed in collaboration with Bristol Myers Squibb

biopharmadive.com
2BMS Acquisition Proceeds
TypeTransaction Fee
Description

2seventy bio was acquired by Bristol Myers Squibb for approximately $286 million in 2025, gaining full control of ABECMA

markets.financialcontent.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

2seventy bio is an immuno-oncology cell therapy company that discovers, develops, and commercializes autologous CAR-T cell therapies. Its flagship commercial product, ABECMA (idecabtagene vicleucel), is a BCMA-directed CAR-T cell therapy approved for adult patients with relapsed or refractory multiple myeloma, marketed in collaboration with Bristol Myers Squibb. The company was founded in 2021 as a spinout from Bluebird bio and was acquired by Bristol Myers Squibb in March 2025.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • ABECMA generated $406 million in sales in 2024
Product overview1 text field

2seventy bio was a biotech company specializing in cell therapy products, particularly CAR-T (chimeric antigen receptor T-cell) therapies. The company was a spinout of Bluebird bio and operated as a focused cell therapy company. Their primary product was ABECMA, a CAR-T therapy for multiple myeloma marketed in partnership with Bristol Myers Squibb. The company also had pipeline assets including bbT369 for lymphoma, which was sold to Regeneron. In March 2025, Bristol Myers Squibb acquired 2seventy bio for approximately $286 million to take full control of ABECMA.

Product and service1 record
1ABECMA (idecabtagene vicleucel)
CategoryCell Therapy - Autologous CAR-T
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Bristol Myers Squibb
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

BMS was the primary strategic partner for 2seventy bio, co-developing and commercializing ABECMA. BMS acquired 2seventy bio in 2025 for $286 million to take full control of the cell therapy. The partnership included manufacturing capacity expansion to meet rising demand for ABECMA.

juve-patent.com
Strategic tierMinorTypeOthersAnnounced on2025-01-01
Description

Patent litigation dispute over CAR-T cell therapy intellectual property. 2seventy bio (BMS-backed) filed lawsuit at the Unified Patent Court against J&J/Legend Biotech over patent rights to Carvykti for multiple myeloma treatment.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Bristol Myers Squibb
TypeBroad incumbent
Description

Global biopharma that co-developed and ultimately acquired 2seventy bio for $286M in 2025. Direct commercialization partner for ABECMA and now owner of the cell therapy franchise; comparable as the integrated incumbent in the same CAR-T commercial value chain.

TypeBroad incumbent
Description

Co-markets Carvykti (BCMA CAR-T for multiple myeloma) with Legend Biotech, the principal direct competitor to ABECMA. Comparable as a large biopharma commercializing an autologous CAR-T therapy in the same indication via a similar specialty treatment-center channel.

TypeDirect peer
Description

Co-developer with J&J of Carvykti, a BCMA-directed autologous CAR-T cell therapy for multiple myeloma. Closest direct peer to 2seventy bio — same modality (autologous CAR-T), same target (BCMA), same indication (multiple myeloma), and the named defendant in 2seventy/BMS's patent litigation.

TypeBroad incumbent
Description

Marketer of Kymriah, the first FDA-approved CAR-T cell therapy. Comparable as an established biopharma operating a commercial autologous CAR-T franchise (hematologic malignancies) and competing in the broader cell therapy commercial landscape that 2seventy participates in.

TypeBroad incumbent
Description

Through Kite Pharma, commercializes Yescarta and Tecartus — leading autologous CAR-T therapies in B-cell malignancies. Comparable as a major incumbent in the autologous CAR-T commercial market with established manufacturing and hospital-channel infrastructure similar to what 2seventy leveraged via BMS.

TypeEmerging player
Description

Clinical-stage developer of allogeneic ("off-the-shelf") CAR-T cell therapies. Comparable as a cell therapy company targeting hematologic cancers with an engineered T-cell platform, representing the next-generation architectural alternative to 2seventy's autologous approach.

7bluebird bio
TypeDirect peer
Description

Original parent of 2seventy bio; spun out the cell therapy division (ABECMA-related assets and team) in 2021. Comparable as a gene and cell therapy company with overlapping scientific lineage, manufacturing know-how, and the same multiple myeloma patient focus.

TypeOthers
Description

Acquired 2seventy's bbT369 lymphoma CAR-T candidate in January 2024 (later discontinued). Comparable as a biopharma actively investing in cell therapy R&D, and relevant as the acquirer of divested 2seventy pipeline assets — a signal of the standalone pipeline's limited perceived value.

TypeEmerging player
Description

Clinical-stage cell therapy company developing allogeneic CAR-T cell therapies for hematologic malignancies. Comparable as a peer cell therapy developer operating in the same engineered T-cell therapy category with overlapping target indications.

TypeEmerging player
Description

Developer of gene-edited cell therapies including allogeneic CAR-T candidates for hematologic cancers. Comparable as a next-generation cell therapy company using novel manufacturing/engineering approaches that could pressure autologous CAR-T incumbents like 2seventy bio.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

2seventy bio

Cell Therapy Oncology Biopharmaceuticals2seventybio.com

2seventy bio was an immuno-oncology cell therapy company, spun out of Bluebird bio in 2021, that developed and commercialized ABECMA, a BCMA-directed CAR-T therapy for relapsed/refractory multiple myeloma, in partnership with Bristol Myers Squibb before being acquired by BMS in March 2025.

What 2seventy bio does

2seventy bio was an immuno-oncology cell therapy company founded in 2021 as a spinout of Bluebird bio, headquartered in Cambridge, Massachusetts. The company discovered, developed, and commercialized autologous CAR-T cell therapies, with its lead and sole commercial product being ABECMA (idecabtagene vicleucel), a BCMA-directed CAR-T therapy for adults with relapsed or refractory multiple myeloma. ABECMA is manufactured using a proprietary process that engineers each patient's own T cells to target BCMA-expressing cells, with a one-time treatment model positioned as a potentially durable option for patients who have exhausted prior lines of therapy. ABECMA generated $406 million in sales in 2024 per the input data, marketed in partnership with Bristol Myers Squibb.

2seventy bio operated a partner-led commercial model: BMS provided the specialty distribution infrastructure, certified treatment center network, and field sales organization that marketed ABECMA to hematologists and oncology centers globally, while 2seventy bio contributed the cell therapy platform, manufacturing expertise, and clinical development. Revenue was generated through a combination of ABECMA product economics shared with BMS and contractual milestones, with cell therapies in this category typically priced at $400,000-$500,000 per patient. The company supplemented ABECMA with early-stage pipeline assets, notably bbT369, a CAR-T candidate for lymphoma that was sold to Regeneron in January 2024 for $5 million.

The company was financed primarily through a $170 million private placement in March 2022 led by a syndicate of healthcare-specialist investors including Bain Capital Life Sciences, EcoR1 Capital, Janus Henderson, and RTW Investments. Over its standalone life, 2seventy bio narrowed its scope to a single commercial asset and was acquired by Bristol Myers Squibb in March 2025 for approximately $286 million, with BMS taking full control of ABECMA and the underlying cell therapy platform.

2seventy bio firmographics

Firmographics
Name
2seventy bio
Legal name
2seventy bio, Inc.
Website
https://2seventybio.com
Company type
Private
Founded year
2021
Operating status
Acquired
Headcount range
51–100 employees
Short description
2seventy bio was an immuno-oncology cell therapy company, spun out of Bluebird bio in 2021, that developed and commercialized ABECMA, a BCMA-directed CAR-T therapy for relapsed/refractory multiple myeloma, in partnership with Bristol Myers Squibb before being acquired by BMS in March 2025.
Ownership category
akta.pro rank

2seventy bio industry classification

Industry
Product category
Cell Therapy Oncology Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • CAR-T cell therapy
  • Immuno-oncology treatments
  • Autologous cell therapy
  • Multiple myeloma therapies
  • Biopharmaceutical development

Where 2seventy bio is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Markets served

2seventy bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Product Sales - ABECMA: Revenue from commercialization of ABECMA (idecabtagene vicleucel), a CAR-T cell therapy for multiple myeloma, marketed in collaboration with Bristol Myers Squibb
  2. BMS Acquisition Proceeds: 2seventy bio was acquired by Bristol Myers Squibb for approximately $286 million in 2025, gaining full control of ABECMA

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

2seventy bio product offering

Product offering

Core offering

2seventy bio is an immuno-oncology cell therapy company that discovers, develops, and commercializes autologous CAR-T cell therapies. Its flagship commercial product, ABECMA (idecabtagene vicleucel), is a BCMA-directed CAR-T cell therapy approved for adult patients with relapsed or refractory multiple myeloma, marketed in collaboration with Bristol Myers Squibb. The company was founded in 2021 as a spinout from Bluebird bio and was acquired by Bristol Myers Squibb in March 2025.

Product overview

2seventy bio was a biotech company specializing in cell therapy products, particularly CAR-T (chimeric antigen receptor T-cell) therapies. The company was a spinout of Bluebird bio and operated as a focused cell therapy company. Their primary product was ABECMA, a CAR-T therapy for multiple myeloma marketed in partnership with Bristol Myers Squibb. The company also had pipeline assets including bbT369 for lymphoma, which was sold to Regeneron. In March 2025, Bristol Myers Squibb acquired 2seventy bio for approximately $286 million to take full control of ABECMA.

Differentiator

Problem solved

Functional benefit

Products and services

  • ABECMA (idecabtagene vicleucel)

Quantifiable outcome

  • ABECMA generated $406 million in sales in 2024

Companies that use 2seventy bio

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

2seventy bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

2seventy bio partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • Bristol Myers SquibbcoreStrategic or Co-development Partner · 1 January 2025BMS was the primary strategic partner for 2seventy bio, co-developing and commercializing ABECMA. BMS acquired 2seventy bio in 2025 for $286 million to take full control of the cell therapy. The partnership included manufacturing capacity expansion to meet rising demand for ABECMA.
  • Johnson & Johnson/Legend BiotechminorOthers · 1 January 2025Patent litigation dispute over CAR-T cell therapy intellectual property. 2seventy bio (BMS-backed) filed lawsuit at the Unified Patent Court against J&J/Legend Biotech over patent rights to Carvykti for multiple myeloma treatment.

Scale indicators5 records

Recent moves7 records

Expansion highlights4 records

2seventy bio competitors and assessment

Company assessment

Broad incumbents

  • Bristol Myers Squibb: Global biopharma that co-developed and ultimately acquired 2seventy bio for $286M in 2025. Direct commercialization partner for ABECMA and now owner of the cell therapy franchise; comparable as the integrated incumbent in the same CAR-T commercial value chain.
  • Johnson & Johnson: Co-markets Carvykti (BCMA CAR-T for multiple myeloma) with Legend Biotech, the principal direct competitor to ABECMA. Comparable as a large biopharma commercializing an autologous CAR-T therapy in the same indication via a similar specialty treatment-center channel.
  • Novartis: Marketer of Kymriah, the first FDA-approved CAR-T cell therapy. Comparable as an established biopharma operating a commercial autologous CAR-T franchise (hematologic malignancies) and competing in the broader cell therapy commercial landscape that 2seventy participates in.
  • Gilead Sciences (Kite Pharma): Through Kite Pharma, commercializes Yescarta and Tecartus — leading autologous CAR-T therapies in B-cell malignancies. Comparable as a major incumbent in the autologous CAR-T commercial market with established manufacturing and hospital-channel infrastructure similar to what 2seventy leveraged via BMS.

Direct peers

  • Legend Biotech: Co-developer with J&J of Carvykti, a BCMA-directed autologous CAR-T cell therapy for multiple myeloma. Closest direct peer to 2seventy bio — same modality (autologous CAR-T), same target (BCMA), same indication (multiple myeloma), and the named defendant in 2seventy/BMS's patent litigation.
  • bluebird bio: Original parent of 2seventy bio; spun out the cell therapy division (ABECMA-related assets and team) in 2021. Comparable as a gene and cell therapy company with overlapping scientific lineage, manufacturing know-how, and the same multiple myeloma patient focus.

Emerging players

  • Allogene Therapeutics: Clinical-stage developer of allogeneic ("off-the-shelf") CAR-T cell therapies. Comparable as a cell therapy company targeting hematologic cancers with an engineered T-cell platform, representing the next-generation architectural alternative to 2seventy's autologous approach.
  • Caribou Biosciences: Clinical-stage cell therapy company developing allogeneic CAR-T cell therapies for hematologic malignancies. Comparable as a peer cell therapy developer operating in the same engineered T-cell therapy category with overlapping target indications.
  • CRISPR Therapeutics: Developer of gene-edited cell therapies including allogeneic CAR-T candidates for hematologic cancers. Comparable as a next-generation cell therapy company using novel manufacturing/engineering approaches that could pressure autologous CAR-T incumbents like 2seventy bio.

Others

  • Regeneron: Acquired 2seventy's bbT369 lymphoma CAR-T candidate in January 2024 (later discontinued). Comparable as a biopharma actively investing in cell therapy R&D, and relevant as the acquirer of divested 2seventy pipeline assets — a signal of the standalone pipeline's limited perceived value.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

2seventy bio social profiles

Digital presence

2seventy bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

2seventy bio leadership team

Management profile

Number of profiles

Profiles8 records

2seventy bio subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

2seventy bio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

2seventy bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 2seventy bio

What does 2seventy bio do?

2seventy bio is an immuno-oncology cell therapy company that discovers, develops, and commercializes autologous CAR-T cell therapies. Its flagship commercial product, ABECMA (idecabtagene vicleucel), is a BCMA-directed CAR-T cell therapy approved for adult patients with relapsed or refractory multiple myeloma, marketed in collaboration with Bristol Myers Squibb. The company was founded in 2021 as a spinout from Bluebird bio and was acquired by Bristol Myers Squibb in March 2025.

Is 2seventy bio a public or private company?

2seventy bio is a private company. It is classified as public and is currently acquired.

When was 2seventy bio founded?

2seventy bio was founded in 2021. It employs 51 to 100 people.

Where is 2seventy bio based?

2seventy bio is headquartered in Cambridge, United States, in the North America region.

How does 2seventy bio make money?

Two revenue lines are on record. Product Sales - ABECMA is the primary driver. The others are BMS Acquisition Proceeds.

Who are 2seventy bio's main competitors?

Broad incumbents on record are Bristol Myers Squibb, Johnson & Johnson, Novartis and Gilead Sciences (Kite Pharma). Direct peers are Legend Biotech and bluebird bio. Emerging players are Allogene Therapeutics, Caribou Biosciences and CRISPR Therapeutics. Regeneron is listed as an others.

Does 2seventy bio have an API?

No public API is recorded for 2seventy bio.

What industry is 2seventy bio in?

2seventy bio's product category is Cell Therapy Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAABAA, Cell Therapy Developers (Autologous). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Motley FoolLooking to Buy Bristol Myers Squibb Stock on the Dip? Read This First.Bristol Myers Squibb shares rebounded after a 11% drop, but the stock faces a patent cliff with Eliquis and Opdivo losing exclusivity in 2028. The company's legacy drugs still account for 46% of revenue, and acquisitions carry integration risks. A 4.2% dividend yield may attract income investors despite the risks.Juve-patentBMS and Johnson & Johnson battle over novel CAR-T cell therapy in EuropeBristol Myers Squibb-backed 2seventy bio has filed a lawsuit at the Unified Patent Court against Johnson & Johnson and Legend Biotech over patent rights to Carvykti, a CAR-T cell therapy for treating multiple myeloma. Johnson & Johnson is simultaneously challenging the contested patent at the UK High Court through a revocation action, and the same patent is also under challenge at the European Patent Office. The dispute centers on intellectual property rights for this bone cancer treatment, with multiple legal battles underway across European jurisdictions.FinancialContent Business PageBristol Myers Squibb (BMS): Navigating the Patent Cliff with a Renewed Pipeline and Strategic AcquisitionsBristol Myers Squibb reported Q3 2025 revenues of $12.2 billion, a 3% year-over-year increase, with its Growth Portfolio surging 18% to $6.9 billion as the company navigates impending patent expirations for key drugs including Revlimid, Eliquis, and Opdivo. The company raised full-year 2025 revenue guidance to $47.5-$48.0 billion and announced continued strategic acquisitions including Orbital Therapeutics ($1.5 billion) and 2seventy bio ($286 million) to strengthen its pipeline in cell therapy, neuroscience, and radiopharmaceuticals. BMS faces significant challenges with generic competition expected to erode 64% of 2025 revenue by decade's end, while also managing operational setbacks including trial failures for Cobenfy and ongoing litigation including a December 2025 lawsuit from the Texas Attorney General.PR NewswireGlobal CAR-T Cell Therapy Market to Hit $217.6Bn by 2035 at 39.75% CAGR | Vantage Market ResearchVantage Market Research released a comprehensive market report projecting the global CAR-T cell therapy market to reach USD 217.6 billion by 2035, growing at a compound annual growth rate of 39.75% from 2025 to 2035, driven by advances in personalized medicine and the expanding portfolio of regulatory-approved therapies. The report highlights over 1,000 active global clinical trials and identifies Johnson & Johnson's Darzalex indication expansion, Bristol Myers Squibb's planned acquisition of 2seventy Bio for USD 286 million, and the FDA approval of Autolus Therapeutics' Aucatzyl as recent developments. High treatment costs ranging from USD 350,000 to USD 500,000 per patient remain a significant market restraint alongside safety risks such as cytokine release syndrome.MarketScreenerALERT: Rowley Law PLLC is Investigating Proposed Acquisition of 2seventy bio, Inc.Rowley Law PLLC is investigating potential securities law violations by 2seventy bio and its board over Bristol Myers Squibb's proposed acquisition. The deal is valued at approximately $286 million, with stockholders receiving $5.00 per share, and is expected to close in the second quarter of 2025.TradingView2seventy bio rises on Bristol Myers buyout dealBristol Myers Squibb agreed to acquire 2seventy bio in an all-cash deal at $5.00 per share, valuing the company at about $286 million. The offer represents an 88% premium to 2seventy bio's closing price of $2.66 on March 7, with the deal expected to close in Q2 2025.Business Insider2seventy Bio to be acquired by Bristol Myers for $5.00 per share in cashBristol Myers Squibb agreed to acquire 2seventy Bio in an all-cash deal at $5.00 per share, valuing the company at approximately $286 million. The transaction includes a second-step merger and is expected to close in the second quarter of 2025, subject to antitrust conditions.ReutersBristol Myers acquires cell therapy partner 2seventy bio for about $286 millionBristol Myers will acquire all outstanding shares of 2seventy Bio for $5 per share, an 88% premium to Friday's close. The deal covers their CAR T-cell therapy Abecma, which generated $242 million in U.S. sales last year. The acquisition is expected to close in the second quarter.Yahoo2seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300MBristol Myers Squibb agreed to acquire 2seventy bio, a cell therapy spinout of Bluebird, in an all-cash deal valuing its equity at $286 million. The offer, about $102 million after cash reserves, gives Bristol Myers rights to Abecma, which generated $406 million in sales last year. The deal is expected to close in the second quarter.